Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma

Annals of Surgery

Volumn 250, Issue 5, 2009, Pages 747-752

  Zischek, Christoph ^a   Niess, Hanno ^a   Ischenko, Ivan ^a   Conrad, Claudius ^a,b,c   Huss, Ralf ^a,c,d   Jauch, Karl Walter ^a   Nelson, Peter J ^a   Bruns, Christiane ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD STEM CELL INSTITUTE   (United States)

^d ROCHE DIAGNOSTICS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; GANCICLOVIR; RANTES; RED FLUORESCENT PROTEIN; THYMIDINE KINASE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CELL HOMING; CELL ISOLATION; CONTROLLED STUDY; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; GENETIC ENGINEERING; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; LIVER METASTASIS; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PANCREATIC TUMOR STROMA; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; STROMA; TREATMENT OUTCOME; UPREGULATION; VIRAL GENE THERAPY;

ANIMALS; CELL MOVEMENT; CHEMOKINE CCL5; GENE THERAPY; GENES, REPORTER; GENES, TRANSGENIC, SUICIDE; INJECTIONS, INTRAPERITONEAL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED C57BL; PANCREATIC NEOPLASMS; PROMOTER REGIONS, GENETIC; SIMPLEXVIRUS; THYMIDINE KINASE; TISSUE ENGINEERING;

EID: 70449429426     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181bd62d0     Document Type: Article

References (44)

1. Ahmed F, Steele JC, Herbert JM, et al. Tumor stroma as a target in cancer. Curr Cancer Drug Targets. 2008;8:447-453.
2. Farrow B, Albo D, Berger DH. The role of the tumor microenvironment in the progression of pancreatic cancer. J Surg Res. 2008;149:319-328.
3. Korc M. Pancreatic cancer-associated stroma production. Am J Surg. 2007; 194(suppl 4):S84-S86.
4. Fritz V, Jorgensen C. Mesenchymal stem cells: an emerging tool for cancer targeting and therapy. Curr Stem Cell Res Ther. 2008;3:32-42.
5. Hall B, Andreeff M, Marini F. The participation of mesenchymal stem cells in tumor stroma formation and their application as targeted-gene delivery vehicles. Handb Exp Pharmacol. 2007:263-283.
6. Kiaris H, Trimis G, Papavassiliou AG. Regulation of tumor-stromal fibroblast interactions: implications in anticancer therapy. Curr Med Chem. 2008;15: 3062-3067.
7. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.
8. Zipori D. The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer Metastasis Rev. 2006;25:459-467.
9. Conrad C, Gupta R, Mohan H, et al. Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther. 2007;7:249-260.
10. Pittenger MF. Mesenchymal stem cells from adult bone marrow. Methods Mol Biol. 2008;449:27-44.
11. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-1659.
12. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557-563.
13. Nakamizo A, Marini F, Amano T, et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005;65: 3307-3318.
14. Nakamura K, Ito Y, Kawano Y, et al. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004;11:1155-1164.
15. Studeny M, Marini FC, Champlin RE, et al. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002;62:3603-3608.
16. Mishra PJ, Glod JW, Banerjee D. Mesenchymal stem cells: flip side of the coin. Cancer Res. 2009;69:1255-1258.
17. Azenshtein E, Luboshits G, Shina S, et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res. 2002;62:1093-1102.
18. Fischer M, Juremalm M, Olsson N, et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int J Cancer. 2003;107:197-201.
19. Soria G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008;267:271-285.
20. Bexell D, Gunnarsson S, Tormin A, et al. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol Ther. 2009;17:183-190.
21. Conrad C, Niess H, Huss R, et al. Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation. 2009;119:281-289.
22. Golumbek PT, Hamzeh FM, Jaffee EM, et al. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmuno-genic tumor cell vaccines. JImmunother (1991). 1992;12:224-230.
23. Mesnil M, Piccoli C, Tiraby G, et al. Bystander killing of cancer cells by herpes simplex virus thymidine kinase gene is mediated by connexins. Proc Natl Acad Sci USA. 1996;93:1831-1835.
24. Von Luttichau I, Notohamiprodjo M, Wechselberger A, et al. Human adult CD34-progenitor cells functionally express the chemokine receptors CCR1, CCR4, CCR7, CXCR5, and CCR10 but not CXCR4. Stem Cells Dev. 2005;14:329-336.
25. Conrad C, Gottgens B, Kinston S, et al. GATA transcription in a small rhodamine 123(low)CD34(+) subpopulation of a peripheral blood-derived CD34(-)CD105(+) mesenchymal cell line. Exp Hematol. 2002;30:887-895.
26. Conrad C, Zeindl-Eberhart E, Moosmann S, et al. Alkaline phosphatase, glutathione-S-transferase-P, and cofilin-1 distinguish multipotent mesenchymal stromal cell lines derived from the bone marrow versus peripheral blood. Stem Cells Dev. 2008;17:23-27.
27. Kumar D, Hosse J, von Toerne C, et al. JNK MAPK pathway regulates constitutive transcription of CCL5 by human NK cells through SP1. J Immunol. 2009;182:1011-1020.
28. Djafarzadeh R, Noessner E, Engelmann H, et al. GPI-anchored TIMP-1 treatment renders renal cell carcinoma sensitive to FAS-meditated killing. Oncogene. 2006;25:1496-1508.
29. Corbett TH, Roberts BJ, Leopold WR, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res. 1984;44:717-726.
30. Liyanage UK, Goedegebuure PS, Moore TT, et al. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006;29:416-424.
31. Segerer S, Banas B, Wornle M, et al. CXCR3 is involved in tubulointerstitial injury in human glomerulonephritis. Am J Pathol. 2004;164:635-649.
32. Morikane K, Tempero RM, Sivinski CL, et al. Organ-specific pancreatic tumor growth properties and tumor immunity. Cancer Immunol Immunother. 1999;47:287-296.
33. Fessele S, Boehlk S, Mojaat A, et al. Molecular and in silico characterization of a promoter module and C/EBP element that mediate LPS-induced RANTES/CCL5 expression in monocytic cells. FASEB J. 2001;15:577-579.
34. Fessele S, Maier H, Zischek C, et al. Regulatory context is a crucial part of gene function. Trends Genet. 2002;18:60-63.
35. von Luettichau I, Nelson PJ, Pattison JM, et al. RANTES chemokine expression in diseased and normal human tissues. Cytokine. 1996;8:89-98.
36. Werner T, Fessele S, Maier H, et al. Computer modeling of promoter organization as a tool to study transcriptional coregulation. FASEB J. 2003; 17:1228-1237.
37. Nelson PJ, Kim HT, Manning WC, et al. Genomic organization and transcriptional regulation of the RANTES chemokine gene. J Immunol. 1993; 151:2601-2612.
38. Huss R, Heil M, Moosmann S, et al. Improved arteriogenesis with simultaneous skeletal muscle repair in ischemic tissue by SCL(+) multipotent adult progenitor cell clones from peripheral blood. J Vasc Res. 2004;41:422-431.
39. Bhowmick NA, Neilson EG, Moses HL. Stromal fibroblasts in cancer initiation and progression. Nature. 2004;432:332-337.
40. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol. 2003;200:429-447.
41. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121:335-348.
42. Orimo A, Weinberg RA. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle. 2006;5:1597-1601.
43. Andoh A, Takaya H, Saotome T, et al. Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology. 2000;119:211-219.
44. Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2006;15:726-731.